Breakthrough - EUR 50 million investment for start-up BrainRepair

Pivotal trial on stem cell treatment for brain damage in newborns fully funded

10-Feb-2023 - Germany

Despite global economic and political crises, a London based group acquires 20% shares of BrainRepair UG, a spin-off of the Ruhr-University Bochum (RUB), Germany, that has developed a unique method based on own (autologous) cord blood stem cells to treat brain damage and cerebral palsy (CP) in newborns affecting 70,000 babies in the EU each year.

Computer-generated image

Symbolic image

BrainRepair UG has been granted the worldwide first ‘Orphan Drug Designations’ (ODD) by the European Commission / European Medicines Agency (EMA) and the Paediatric Investigation Plan (PIP) for the pivotal trial has been approved. The ODD guarantees market exclusivity in all EU member states for 12 years upon market authorisation.

“We are particularly grateful to Olaf Bolwerk, Johan Nijboer, and Dr. Alexander van der Speld who masterminded the transaction to fund our way towards market authorisation”, Prof. Dr. Arne Jensen stresses and continues, “All our personal, scientific, clinical, and philanthropic efforts serve the ultimate goal – to combat cerebral palsy, the most common disability in childhood – and stop CP in children!”

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...

Something is happening in the life science industry ...

This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.